Cardiovascular Systems (CSII) has designed its Diamondback 360 device for removing arterial calcium buildups in vessels before stenting. The FDA approved the device for the treatment of leg and heart vessels in 2007, but later last year the agency cleared the device for calcified coronary arteries, a $1.5 billion market dominated by last generation technologies, according to CSII CEO David Martin. He further said:
FDA approval of our Diamondback 360 Coronary OAS allows us to bring to market the first new coronary atherectomy system in more than two decades. Severe coronary arterial calcium is an underestimated problem in medicine, with limited options for treatment.
The opportunity is huge and I believe this could eventually turn the company around and drive its bottom-line in the positive territory. The stock, after years of underperformance, has started to move up over the past few quarters and I feel there is